Cargando…

Suppression of Lung Adenocarcinoma Progression by Nkx2-1

Despite the high prevalence and poor outcome of patients with metastatic lung cancer, the mechanisms of tumour progression and metastasis remain largely uncharacterized. We modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS1 and inactivation of the p53-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Winslow, Monte M., Dayton, Talya L., Verhaak, Roel G. W., Kim-Kiselak, Caroline, Snyder, Eric L., Feldser, David M., Hubbard, Diana D., DuPage, Michel J., Whittaker, Charles A., Hoersch, Sebastian, Yoon, Stephanie, Crowley, Denise, Bronson, Roderick T., Chiang, Derek Y., Meyerson, Matthew, Jacks, Tyler
Formato: Texto
Lenguaje:English
Publicado: 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088778/
https://www.ncbi.nlm.nih.gov/pubmed/21471965
http://dx.doi.org/10.1038/nature09881
_version_ 1782202931442876416
author Winslow, Monte M.
Dayton, Talya L.
Verhaak, Roel G. W.
Kim-Kiselak, Caroline
Snyder, Eric L.
Feldser, David M.
Hubbard, Diana D.
DuPage, Michel J.
Whittaker, Charles A.
Hoersch, Sebastian
Yoon, Stephanie
Crowley, Denise
Bronson, Roderick T.
Chiang, Derek Y.
Meyerson, Matthew
Jacks, Tyler
author_facet Winslow, Monte M.
Dayton, Talya L.
Verhaak, Roel G. W.
Kim-Kiselak, Caroline
Snyder, Eric L.
Feldser, David M.
Hubbard, Diana D.
DuPage, Michel J.
Whittaker, Charles A.
Hoersch, Sebastian
Yoon, Stephanie
Crowley, Denise
Bronson, Roderick T.
Chiang, Derek Y.
Meyerson, Matthew
Jacks, Tyler
author_sort Winslow, Monte M.
collection PubMed
description Despite the high prevalence and poor outcome of patients with metastatic lung cancer, the mechanisms of tumour progression and metastasis remain largely uncharacterized. We modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS1 and inactivation of the p53-pathway2, using conditional alleles in mice3–5. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development4. Although tumours are initiated synchronously by defined genetic alterations, only a subset become malignant, suggesting that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK-2 related homeobox transcription factor Nkx2-1 (Ttf-1/Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1-negativity is pathognomonic of high-grade poorly differentiated tumours. Gain-and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1 regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically-restricted chromatin regulator Hmga2. While focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function6–9, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability, and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor.
format Text
id pubmed-3088778
institution National Center for Biotechnology Information
language English
publishDate 2011
record_format MEDLINE/PubMed
spelling pubmed-30887782011-11-05 Suppression of Lung Adenocarcinoma Progression by Nkx2-1 Winslow, Monte M. Dayton, Talya L. Verhaak, Roel G. W. Kim-Kiselak, Caroline Snyder, Eric L. Feldser, David M. Hubbard, Diana D. DuPage, Michel J. Whittaker, Charles A. Hoersch, Sebastian Yoon, Stephanie Crowley, Denise Bronson, Roderick T. Chiang, Derek Y. Meyerson, Matthew Jacks, Tyler Nature Article Despite the high prevalence and poor outcome of patients with metastatic lung cancer, the mechanisms of tumour progression and metastasis remain largely uncharacterized. We modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS1 and inactivation of the p53-pathway2, using conditional alleles in mice3–5. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development4. Although tumours are initiated synchronously by defined genetic alterations, only a subset become malignant, suggesting that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK-2 related homeobox transcription factor Nkx2-1 (Ttf-1/Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1-negativity is pathognomonic of high-grade poorly differentiated tumours. Gain-and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1 regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically-restricted chromatin regulator Hmga2. While focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function6–9, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability, and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor. 2011-04-06 2011-05-05 /pmc/articles/PMC3088778/ /pubmed/21471965 http://dx.doi.org/10.1038/nature09881 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Winslow, Monte M.
Dayton, Talya L.
Verhaak, Roel G. W.
Kim-Kiselak, Caroline
Snyder, Eric L.
Feldser, David M.
Hubbard, Diana D.
DuPage, Michel J.
Whittaker, Charles A.
Hoersch, Sebastian
Yoon, Stephanie
Crowley, Denise
Bronson, Roderick T.
Chiang, Derek Y.
Meyerson, Matthew
Jacks, Tyler
Suppression of Lung Adenocarcinoma Progression by Nkx2-1
title Suppression of Lung Adenocarcinoma Progression by Nkx2-1
title_full Suppression of Lung Adenocarcinoma Progression by Nkx2-1
title_fullStr Suppression of Lung Adenocarcinoma Progression by Nkx2-1
title_full_unstemmed Suppression of Lung Adenocarcinoma Progression by Nkx2-1
title_short Suppression of Lung Adenocarcinoma Progression by Nkx2-1
title_sort suppression of lung adenocarcinoma progression by nkx2-1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088778/
https://www.ncbi.nlm.nih.gov/pubmed/21471965
http://dx.doi.org/10.1038/nature09881
work_keys_str_mv AT winslowmontem suppressionoflungadenocarcinomaprogressionbynkx21
AT daytontalyal suppressionoflungadenocarcinomaprogressionbynkx21
AT verhaakroelgw suppressionoflungadenocarcinomaprogressionbynkx21
AT kimkiselakcaroline suppressionoflungadenocarcinomaprogressionbynkx21
AT snyderericl suppressionoflungadenocarcinomaprogressionbynkx21
AT feldserdavidm suppressionoflungadenocarcinomaprogressionbynkx21
AT hubbarddianad suppressionoflungadenocarcinomaprogressionbynkx21
AT dupagemichelj suppressionoflungadenocarcinomaprogressionbynkx21
AT whittakercharlesa suppressionoflungadenocarcinomaprogressionbynkx21
AT hoerschsebastian suppressionoflungadenocarcinomaprogressionbynkx21
AT yoonstephanie suppressionoflungadenocarcinomaprogressionbynkx21
AT crowleydenise suppressionoflungadenocarcinomaprogressionbynkx21
AT bronsonroderickt suppressionoflungadenocarcinomaprogressionbynkx21
AT chiangdereky suppressionoflungadenocarcinomaprogressionbynkx21
AT meyersonmatthew suppressionoflungadenocarcinomaprogressionbynkx21
AT jackstyler suppressionoflungadenocarcinomaprogressionbynkx21